FGFR2b
Showing 1 - 25 of >10,000
Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma Trial in Canada, Germany, United States (Infigratinib)
Not yet recruiting
- Advanced Solid Tumor
- +2 more
-
Palo Alto, California
- +9 more
Aug 2, 2022
Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)
Recruiting
- Breast Cancer
- +3 more
- Infigratinib
- +3 more
-
Stanford, CaliforniaStanford University
Feb 16, 2022
Squamous-Cell Non-Small-Cell Lung Cancer Trial in Worldwide (Bemarituzumab, Docetaxel)
Recruiting
- Squamous-Cell Non-Small-Cell Lung Cancer
-
Orange, California
- +24 more
Jul 27, 2022
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, NSCLC, KRAS Gene Mutation Trial in Santa Monica,
Recruiting
- Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations
- +2 more
- Futibatinib and Binimetinib
-
Santa Monica, California
- +2 more
Jun 2, 2022
Urothelial Carcinoma Trial in Shanghai (AZD4547)
Recruiting
- Urothelial Carcinoma
-
Shanghai, Shanghai, ChinaFudan University Cancer Hospital
Oct 20, 2021
FGFR Testing by Either ctDNA Blood Testing or Standard Tumor
Recruiting
- Metastatic Bladder Cancer
- Metastatic Urothelial Carcinoma
- FGFR Testing
-
Calgary, Alberta, Canada
- +6 more
Nov 8, 2023
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in Worldwide (Bemarituzumab, Nivolumab, mFOLFOX6)
Recruiting
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Bemarituzumab
- +3 more
-
Phoenix, Arizona
- +119 more
Feb 1, 2023
Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,
Recruiting
- Metastatic Gastric Cancer
- +2 more
- Nivolumab
- +2 more
-
New York, New YorkBureau for Cancer Research
May 10, 2023
Cholangiocarcinoma, Liver Cancer Trial in Houston (Infigratinib, Atezolizumab, Bevacizumab)
Not yet recruiting
- Cholangiocarcinoma
- Liver Cancer
- Infigratinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life
Active, not recruiting
- FGFR1 Gene Amplification
- +18 more
- Pemigatinib
- Quality-of-Life Assessment
-
Scottsdale, Arizona
- +5 more
Oct 18, 2022
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in Worldwide (Bemarituzumab, mFOLFOX6, Placebo)
Recruiting
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Bemarituzumab
- +2 more
-
Anchorage, Alaska
- +140 more
Aug 11, 2022
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York
Recruiting
- Advanced Solid Tumor
- +13 more
- [225Ac]-FPI-1966
- +2 more
-
Duarte, California
- +3 more
Oct 25, 2022
Advanced Intrahepatic Cholangiocarcinoma Trial (Pemigatinib)
Not yet recruiting
- Advanced Intrahepatic Cholangiocarcinoma
- (no location specified)
Sep 30, 2022
Urothelial Carcinoma Trial in Worldwide (Rogaratinib (BAY1163877), Atezolizumab)
Active, not recruiting
- Urothelial Carcinoma
- Rogaratinib (BAY1163877)
- Atezolizumab
-
Tucson, Arizona
- +29 more
Aug 17, 2022
Cholangiocarcinoma Trial in Shanghai (Pemigatinib)
Active, not recruiting
- Cholangiocarcinoma
-
Shanghai, Shanghai, ChinaZhongshan Hospital Affiliated to Fudan University
Oct 3, 2022
Solid Tumor Trial in Worldwide (Debio 1347)
Terminated
- Solid Tumor
- Debio 1347
-
Scottsdale, Arizona
- +104 more
Mar 30, 2022
Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)
Recruiting
- Urothelial Carcinoma
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 8, 2023
Refractory Solid Tumors Trial in Seoul (pazopanib)
Completed
- Refractory Solid Tumors
-
Seoul, Korea, Republic ofSamsung Medical Center
Jun 13, 2022
Breast Cancer Trial in Tianjin (Pemigatinib Pill)
Recruiting
- Breast Cancer
- Pemigatinib Pill
-
Tianjin, Tianjin, ChinaBreast Oncology, Tianjin Medical University Cancer Institute and
Sep 26, 2022
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)
Not yet recruiting
- Locally Advanced Urothelial Carcinoma
- +3 more
- (no location specified)
Sep 15, 2022
Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma Trial in
Recruiting
- Advanced Hepatocellular Carcinoma
- +4 more
- Futibatinib
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 30, 2023